My reading of the "tea leaves" is that most patients in our M2M study get better on their own and therefore difficult to achieve significant differences at day 14. NEWS2 scores patients earlier and for more objective clinical signs/symptoms therefore we have significant differences. See below from clinicaltrials.gov on our M2M trial.

M2M Primary End Point
Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough) [ Time Frame: Day 14 ]

M2M Secondary End Point
Change from baseline in National Early Warning Score 2 (NEWS2) [ Time Frame: Days 3, 7, and 14 ]